Enosi Life Sciences Appoints Biotech, Pharma and Venture Capital Veteran Dr. James N. Woody as Executive Chairman

Dr. James Woody’s leadership qualities and experience leading innovative pharmaceutical ventures and raising funds will power Enosi’s development of second-generation anti-TNF therapeutics for inflammatory autoimmune diseases and cancer.

SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) — Enosi Life Sciences, a drug research and development company focused on providing industry-leading therapeutics for inflammatory autoimmune diseases and cancer, announced today its appointment of antibody therapeutics pioneer Dr. James N. Woody as Executive Chairman.

Dr. Woody brings to Enosi more than 25 years of leadership experience in the biotech, pharmaceutical and venture capital sectors after reaching the top of Navy Medical research. He possesses medical and research expertise in a wide range of disciplines, including oncology and antibody therapeutics. Dr. Woody led the Centocor team that developed Remicade, the first tumor necrosis factor (TNF) inhibitor biologic, working with Sir Ravinder Maini and Sir Marc Feldmann. He will apply his broad ranging experience in biomedical research, drug development and management to lead Enosi’s development of anti-TNF therapeutics for inflammation, autoimmune diseases and cancer.

“Creating new and better therapeutics for cancer and autoimmune diseases alike requires creativity and a wealth of knowledge in multiple schools of thought, and hence appointing Dr. James N. Woody as our Executive Director adds a great deal of relevant experience to Enosi Life Sciences,” said Dr. H. Michael Shepard, President and CSO of Enosi Life Sciences. “Dr. Woody is a proven leader in the development of antibody therapeutics, and his expertise in multiple areas of medicine, along with his deep roots and networking connections in the biotech, pharmaceutical and venture capital spaces, will help Enosi successfully develop and deliver more effective and targeted therapeutics to the patients whose lives they could transform.”

“We believe that specifically inhibiting TNF receptors has huge potential in addressing autoimmune diseases and cancer, so anti-TNF pioneer and collaborator Dr. Woody joining the Enosi team will enhance our capacity to develop these improved therapeutics,” said Sir Marc Feldmann, Co-founder and Board Member of Enosi Life Sciences. “Dr. Woody has also led multiple biotech companies through acquisition, so in addition to his scientific track record, he has created significant value for investors and other key stakeholders. I have worked with him since the 1970s, including the pleasure of working together developing Remicade. We are delighted to have him join the Enosi team.”

Dr. Woody has also served as the Chief Executive Officer of MaraBio Systems, Chairman of the Board of Viracta Therapeutics, General Partner of Latterell Venture Partners, Founding President and CEO of OncoMed Pharmaceuticals, President and General Manager of Roche Biosciences (formerly Syntex Pharmaceuticals), Senior Vice President and Chief Scientific Officer of Centocor, and Commanding Officer and Director of the U.S. Naval Medical Research and Development Command, where he and his colleagues founded the National Marrow Donor Program, which provides matched bone marrow for recipients without matched donors. He holds a Doctor of Medicine from the Loma Linda University School of Medicine, and a Doctor of Philosophy in Immunology from University College London.

About Enosi Life Sciences
Enosi Life Sciences is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and cancer. The company was founded by world-renowned scientists Professor Sir Marc Feldmann, who discovered anti-tumor necrosis factor (anti-TNF) therapy as an effective treatment for rheumatoid arthritis and other autoimmune diseases (Lasker Award, 2003); and Dr. H. Michael Shepard, whose research in humanized antibodies created the first monoclonal antibody therapy targeting cancer oncogene encoded-proteins (Lasker award, 2019). Enosi Life Sciences combines Feldmann and Shepard’s expertise in cancer and autoimmune diseases with Executive Chairman Dr. James N. Woody’s unique combination of medical, scientific and management expertise to expand therapeutic options. To learn more about Enosi Life Sciences, visit www.enosi-life.com.

Company Contact
Ozan Pamir, CFO
Enosi Life Sciences
ozan@enosi-lifestyle-live.ydjmnbeysm-ypj682ovp6l2.p.runcloud.link
858-350-4392


IR Contact
Tom Becker
Enosi Life Sciences
investment@enositherapeutics.com
702-445-7038

Media Relations Contact
Kate Caruso-Sharpe
FischTank PR
enosi@fischtankpr.com
646-699-1534

Group 3 Copy 2

James N. Woody

Executive Chairman

  • Jim brings more than 25 years of pharmaceutical research and management experience to Enosi.
  • In addition to his duties as a consultant to LVP, where he served as a General Partner for 14 years, Jim is currently Chairman of Viracta Therapeutics, a company focusing on unique therapies for virally induced cancers.  
  • He was the founding CEO of OncoMed Pharmaceuticals, a cancer therapeutic antibody company. He was the Board member for both ForteBio, and Protein Simple, both successfully acquired. Jim was formerly President and GM of Roche Bioscience (former Syntex) in Palo Alto, CA. 
  • Previously, Jim served as Chief Scientific Officer and Senior Vice President of R&D for Centocor. While at Centocor, Jim’s team developed the blockbuster drug Remicade. 
  • Jim served as a Navy Medical Officer, and was Head of the Navy Transplant Research Program. With his colleagues and with both Navy and Congressional support, founded the National Marrow Donor Program. 
  • He was promoted to Commanding Officer and Director, US Naval Medical Research and Development Command in Bethesda Maryland. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War and was awarded the Marine Corps/US Navy Legion of Merit for his service. 
  • Jim served as Chairman of the Silicon Valley Leadership Group representing over 120 Silicon Valley Companies, is a board member of the Lucile Packard Children’s Hospital (Stanford).
  • Jim holds an M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England. He was Professor of Pediatrics and Microbiology at Georgetown University School of Medicine 1982-1996. He has authored or co-authored over 140 publications.
Group 3 Copy

H. Michael Shepard, Ph.D.

CEO & Co-founder

  • Dr. H. Michael Shepard is a global, leading authority on cancer research and therapeutics.
  • Best known for his invention of “Herceptin”/Trastuzumab, which has remained one of the most profitable platforms for Roche (>$7B USD).
  • Dr. Shepard is a highly-experienced and respected leader with many successful ventures in this field – working at Genentech (sold to Roche – $46.8 B USD), Canji, Inc. (bought by Scheirng-Plough) and Halozyme (now valued at $2.6B USD).
  • Widely acknowledged biomarker pioneer and recognized worldwide, Dr. Shepard has received the 2019 Albert Lasker Award and the Warren Alpert Prize, among many other professional accolades.

Enosi Team SirMarc Lasker Circle

Sir Marc Feldmann, M.D. Ph.D.

Director & Co-founder

  • Sir Marc Feldmann is a preeminent immunologist, and an Emeritus Professor at the University of Oxford.
  • With Sir Ravinder Maini, identified TNF as a target. Trials of Infliximab (Remicade) they led were successful, and prompted J&J’s $4.9B USD acquisition of Centocor.
  • Anti-TNF sales > $50B USD globally.
  • Professor Sir Marc Feldmann is a Fellow of the Royal Society , of Australian Academy and a Foreign Member of the US National Academy of Sciences; he was knighted in 2010 and received the Australian equivalent.
  • He has received many accolades including the Albert Lasker Award, the Crafoord Prize, the Canada Gairdner Award, the Paul Janssen Award, the Ernst Schering Award.